RESUMO
Many techniques designed to gain compliance to a request are presented in the social psychological literature. However, the lure technique has received little attention from scientists. This technique, also called bait-and-switch, is used to influence people's choices and involves three stages: (1) individuals are led to make a rewarding decision to carry out a given behavior; (2) they are informed of the impossibility of carrying out this behavior; (3) a new but less rewarding decision is proposed. Only one formal study has been published on this technique, which failed to control two key methodological factors: the status of the participants and the solicitor, and the delay between the initial decision and the target request. These two factors were controlled in this study. Outside a French campus, 40 female students in the 18-22 age range were solicited by a student to participate in a pleasant experiment for which they would be remunerated. One minute after accepting, they were informed that the number of participants was reached, and they were no longer needed. The solicitor then proposed a different task that was less interesting and not remunerated. Greater compliance with the final request was found in the lure condition (70%) than in the control condition (35%) in which the final request was addressed immediately. The results confirm the effectiveness of the lure technique to increase compliance and show that its effectiveness is not dependent on the solicitor's status.
Assuntos
Comportamento de Escolha/fisiologia , Recompensa , Comportamento Social , Adolescente , Adulto , Feminino , Humanos , Relações Interpessoais , Fatores de Tempo , Adulto JovemRESUMO
INTRODUCTION: This trial evaluates whether daily low-dose aspirin initiated before 16 weeks of gestation can reduce preeclampsia and fetal growth restriction in nulliparous women identified by first-trimester uterine artery Dopplers as at high risk of preeclampsia. METHODS: This randomized, blinded, placebo-controlled, parallel-group trial took place in 17 French obstetric departments providing antenatal care. Pregnant nulliparous women aged ≥ 18 years with a singleton pregnancy at a gestational age < 16 weeks of gestation with a lowest pulsatility index ≥ 1.7 or a bilateral protodiastolic notching for both uterine arteries on an ultrasound performed between 11+0 and 13+6 weeks by a certified sonographer were randomized at a 1:1 ratio to 160 mg of low-dose aspirin or to placebo to be taken daily from inclusion to their 34th week of gestation. The main outcome was preeclampsia or a birthweight ≤ 5th percentile. Other outcomes included preeclampsia, severe preeclampsia, preterm preeclampsia, preterm delivery before 34 weeks, mode of delivery, type of anesthesia, birthweight ≤ 5th percentile and perinatal death. RESULTS: The trial was interrupted due to recruiting difficulties. Between June 2012 and June 2016, 1104 women were randomized, two withdrew consent, and two had terminations of pregnancies. Preeclampsia or a birthweight ≤ 5th percentile occurred in 88 (16.0%) women in the low-dose aspirin group and in 79 (14.4%) in the placebo group (proportion difference 1.6 [-2.6; 5.9] p = 0.45). The two groups did not differ significantly for the secondary outcomes. CONCLUSION: Low-dose aspirin was not associated with a lower rate of either preeclampsia or birthweight ≤ 5th percentile in women identified by their first-trimester uterine artery Doppler as at high risk of preeclampsia. TRIAL REGISTRATION: (NCT0172946).
Assuntos
Pré-Eclâmpsia , Artéria Uterina , Recém-Nascido , Feminino , Gravidez , Humanos , Masculino , Artéria Uterina/diagnóstico por imagem , Pré-Eclâmpsia/prevenção & controle , Pré-Eclâmpsia/tratamento farmacológico , Peso ao Nascer , Aspirina/uso terapêutico , Primeiro Trimestre da GravidezRESUMO
OBJECTIVE: Determine whether dyssynergic defecation is a risk factor for third- or fourth-degree tear during a first vaginal delivery. STUDY DESIGN: A retrospective case-control study was conducted on 549 primiparous women. The case group (n = 140) sustained an anal sphincter tear and the control group (n = 409) had a perineal laceration lower or equal to a second-degree tear. The Knowles-Eccersley-Scott Symptom questionnaire identified women who had dyssynergic defecation. A logistic regression analysis was performed. RESULTS: Anal sphincter tear were 2.94 times higher for women reporting dyssynergic defecation (P = .002; 95% confidence interval [CI], 1.47-5.88). Odds ratios (ORs) were also significant for forceps (P < .001; OR, 6.90; 95% CI, 3.27-14.59), vacuum extraction (P = .009; OR, 2.36; 95% CI, 1.17-4.76), median episiotomy (P = .009; OR, 2.71; 95% CI, 1.54-4.78), and high infant weight (P < .001; OR, 2.25 for each 500 g increase; 95% CI, 1.69-2.99). CONCLUSION: Dyssynergic defecation seems to increase anal sphincter tear, but prospective studies are needed to confirm the association.
Assuntos
Canal Anal/lesões , Defecação , Parto Obstétrico/efeitos adversos , Períneo/lesões , Complicações na Gravidez/epidemiologia , Doenças Retais/epidemiologia , Adulto , Estudos de Casos e Controles , Parto Obstétrico/estatística & dados numéricos , Feminino , Humanos , Modelos Logísticos , Gravidez , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Inquéritos e QuestionáriosAssuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Dermatite Fotoalérgica/etiologia , Piroxicam/efeitos adversos , Administração Cutânea , Adulto , Anti-Inflamatórios não Esteroides/administração & dosagem , Dermatite Fotoalérgica/patologia , Humanos , Masculino , Piroxicam/administração & dosagem , Fatores de TempoRESUMO
"Foot-in-the-door" is a well-known compliance technique which increases compliance to a request. Many investigations with this paradigm have generally used prosocial requests to test its effect. Evaluation of the effect of foot-in-the-door was carried out with a courtship request. 360 young women were solicited in the street to accept having a drink with a young male confederate. In the foot-in-the-door condition, before being solicited to have a drink, the young woman was asked to give directions to the confederate or to give him a light for his cigarette. Analysis showed foot-in-the-door was associated with greater compliance to the second request. The theoretical implication of such results with this nonprosocial request are discussed.
Assuntos
Teoria Psicológica , Comportamento Sexual , Comportamento Social , Adolescente , Adulto , Feminino , Humanos , Masculino , Comportamento Sexual/psicologia , Inquéritos e QuestionáriosRESUMO
The deployment of electronic health record systems is deemed to play a decisive role in the transformations currently being implemented in primary care medical practices. This study aims to characterize electronic health record systems from the perspective of family physicians. To achieve this goal, we conducted a survey of physicians practising in private clinics located in Quebec, Canada. We used valid responses from 331 respondents who were found to be representative of the larger population. Data provided by the physicians using the top three electronic health record software products were analysed in order to obtain statistically adequate sub-sample sizes. Significant differences were observed among the three products with regard to their functional capability. The extent to which each of the electronic health record functionalities are used by physicians also varied significantly. Our results confirm that the electronic health record artefact 'does matter', its clinical functionalities explaining why certain physicians make more extended use of their system than others.
RESUMO
BACKGROUND: Renal toxicity induced by cisplatin (CisPt) is a clinical issue in patients with or without chronic kidney disease (CKD). Proximal tubular injury can result in acute kidney injury (AKI), which may compromise the course of chemotherapy and the prognosis. The purpose of this study was to investigate the time course of urinary markers of acute tubulotoxicity and to assess the usefulness of such monitoring in a routine clinical setting. METHODS: This work is an open prospective pilot study carried out among 23 patients receiving a platinum-based chemotherapy. Individual comorbidities, plasma parameters of kidney function (urea, creatinine) and estimated glomerular filtration rate were registered. Urinary excretion of leucine aminopeptidase, neutrophil gelatinase-associated lipocalin, cystatin C, liver fatty acid-binding protein and interleukin-18 were monitored during successive chemotherapy cycles. Episodes of AKI were identified according to KDIGO (Kidney Disease Improving Global Outcomes) 2012 guidelines. RESULTS: A total of 28 patients were recruited; among them 23 agreed to be part of the study, of whom 18 received CisPt and 5 carbo- or oxaliplatin. Of the 18 CisPt patients, 12 had a preexisting CKD. Sixteen AKI episodes were observed in 13 patients receiving CisPt with a pejorative evolution in seven cases (partial recovery of the renal function); a transient but dramatic increase in urinary biomarkers was observed 3 h after chemotherapy initiation, whereas plasma creatinine rise appeared 72 h after the end of CisPt treatment. Identified precipitating factors included: dehydration due to lack of fluid intake or diuretic use, exposure to high CisPt doses, regular use of nonsteroidal anti-inflammatory drugs and/or iodinated contrast agents and sepsis. CONCLUSION: Even if numerous precipitating factors could be avoided, the monitoring of urinary markers seemed helpful for the early detection of subclinical AKI induced during CisPt chemotherapy.
RESUMO
PURPOSE: To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3(168-176) and MAGE-1(161-169), which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs). MATERIALS AND METHODS: The vaccination schedule comprised four sequential injections of the recombinant virus, followed by three booster vaccinations with the MAGE-3(168-176) and MAGE-1(161-169) peptides. The vaccines were administered, both intradermally and subcutaneously, at 3-week intervals. RESULTS: Forty patients with advanced cancer were treated, including 37 melanoma patients. The vaccines were generally well tolerated with moderate adverse events, consisting mainly of transient inflammatory reactions at the virus injection sites. Among the 30 melanoma patients assessable for tumor response, a partial response was observed in one patient, and disease stabilization in two others. The remaining patients had progressive disease. Among the patients with stable or progressive disease, five showed evidence of tumor regression. A CTL response against the MAGE-3 vaccine antigen was detected in three of four patients with tumor regression, and in only one of 11 patients without regression. CONCLUSION: Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients. There is a significant correlation between tumor regression and CTL response. The contribution of vaccine-induced CTL in the tumor regression process is discussed in view of the immunologic events that could be analyzed in detail in one patient.
Assuntos
Vacinas Anticâncer/imunologia , Melanoma/terapia , Vacinas Virais/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos de Neoplasias/imunologia , Vírus da Varíola dos Canários/imunologia , Progressão da Doença , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Melanoma/imunologia , Antígenos Específicos de Melanoma , Pessoa de Meia-Idade , Proteínas de Neoplasias/imunologia , Linfócitos T Citotóxicos/imunologia , Resultado do TratamentoRESUMO
The characterization of tumor antigens recognized by T lymphocytes has provided the opportunity to immunize cancer patients with well-defined peptides. Differentiation and tumor-specific antigens are expressed in a significant proportion of patients with cancer. Pilot studies have involved many patients with melanoma. No major toxicity has been reported after peptide vaccination. The clinical efficacy of peptide vaccines is limited to a minority of patients and the response rate is less than 20%. Some regressions have been complete and long-lasting. The development of this approach, and that of other methods to deliver tumor antigens, depends on clinical empirism to improve the therapeutic efficacy of the vaccine as well as the accurate understanding of the immune mechanisms involved in vivo.
Assuntos
Antígenos de Neoplasias/imunologia , Vacinas Anticâncer , Melanoma/imunologia , Melanoma/terapia , Proteínas de Neoplasias/imunologia , Vacinas de Subunidades Antigênicas , Vacinas Anticâncer/imunologia , Vacinas Anticâncer/uso terapêutico , Ensaios Clínicos como Assunto , Citocinas/imunologia , Humanos , Proteínas Recombinantes/imunologia , Linfócitos T/imunologia , Vacinas de Subunidades Antigênicas/imunologia , Vacinas de Subunidades Antigênicas/uso terapêuticoRESUMO
The purpose of this study was to test melanoma vaccines consisting of peptides and immunological adjuvants for optimal immunogenicity and to evaluate laboratory immune monitoring for in vivo relevance. Forty-nine HLA-A2 positive patients with Melan-A positive melanoma were repeatedly vaccinated with Melan-A peptide, with or without immune adjuvant AS02B (QS21 and MPL) or IFA. Peptide-specific CD8 T cells in PBLs were analyzed ex vivo using fluorescent HLA-A2/Melan-A multimers and IFN-gamma ELISPOT assays. The vaccines were well tolerated. In vivo expansion of Melan-A-specific CD8 T cells was observed in 13 patients (1/12 after vaccination with peptide in AS02B and 12/17 after vaccination with peptide in IFA). The T cells produced IFN-gamma and downregulated CD45RA and CD28. T-cell responses correlated with inflammatory skin reactions at vaccine injection sites (P < 0.001) and with DTH reaction to Melan-A peptide (P < 0.01). Twenty-six of 32 evaluable patients showed progressive disease, whereas 4 patients had stable disease. The two patients with the strongest Melan-A-specific T-cell responses experienced regression of metastases in skin, lymph nodes, and lung. We conclude that repeated vaccination with Melan-A peptide in IFA frequently leads to sustained responses of specific CD8 T cells that are detectable ex vivo and correlate with inflammatory skin reactions.
Assuntos
Linfócitos T CD8-Positivos/imunologia , Vacinas Anticâncer/imunologia , Melanoma/imunologia , Proteínas de Neoplasias/imunologia , Adolescente , Adulto , Idoso , Antígenos de Neoplasias , Vacinas Anticâncer/toxicidade , Dermatite/etiologia , Progressão da Doença , Feminino , Adjuvante de Freund/uso terapêutico , Humanos , Lipídeos/uso terapêutico , Ativação Linfocitária , Antígeno MART-1 , Masculino , Melanoma/diagnóstico , Melanoma/terapia , Pessoa de Meia-Idade , Monitorização Imunológica , Peptídeos/imunologia , Peptídeos/uso terapêutico , Proteínas da Matriz Viral/imunologiaRESUMO
Melanoma patients were injected with various vaccines containing a MAGE-A3 peptide presented by HLA-DP4. Anti-MAGE-A3.DP4 T cells were not detectable in the blood before vaccination, but their frequencies after vaccination ranged from 2 x 10(-6) to 2 x 10(-3) among the CD4(+) blood T lymphocytes of the patients. The CD4(+) blood T lymphocytes that stained ex vivo with HLA-DP4 tetramers folded with the MAGE-A3 peptide were selected by flow cytometry and amplified under clonal conditions. About 5% of the CD4(+) T-cell clones that recognized the MAGE-A3.DP4 antigen had a CD25(+) phenotype in the resting state. These CD25(+) clones had a high capacity to suppress the proliferation of another T-cell clone after peptide stimulation in vitro. Most of them had high FOXP3 expression in the resting state and an unmethylated FOXP3 intron 1. They produced active transforming growth factor-beta but none of cytokines IFN-gamma, interleukin-2 (IL-2), IL-4, IL-5, and IL-10. About 20% of CD25(-) clones had a significant but lower suppressive activity. Most of the CD25(-) clonal populations contained cells that expressed FOXP3 in the resting state, but FOXP3 demethylation was not observed. We conclude that MAGE-A3.DP4 vaccination can produce CD4(+) T cells that may exert regulatory T-cell function in vivo.
Assuntos
Antígenos de Neoplasias/imunologia , Linfócitos T CD4-Positivos/imunologia , Vacinas Anticâncer/uso terapêutico , Melanoma/imunologia , Proteínas de Neoplasias/imunologia , Linfócitos T Reguladores/imunologia , Vacinas de Subunidades Antigênicas/uso terapêutico , Antígenos de Neoplasias/genética , Linhagem Celular Tumoral , Células Clonais/imunologia , Citometria de Fluxo , Fatores de Transcrição Forkhead/genética , Humanos , Interleucina-2/farmacologia , Interleucina-4/farmacologia , Interleucina-7/farmacologia , Ativação Linfocitária/efeitos dos fármacos , Proteínas de Neoplasias/genética , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/imunologia , Linfócitos T/imunologiaRESUMO
Quantitative evaluation of T cell responses of patients receiving antitumoral vaccination with a protein is difficult because of the large number of possible HLA-peptide combinations that could be targeted by the response. To evaluate the responses of patients vaccinated with protein MAGE-3, we have developed an approach that involves overnight stimulation of blood T cells with autologous dendritic cells loaded with the protein, sorting by flow cytometry of the T cells that produce IFN-gamma, cloning of these cells, and evaluation of the number of T cell clones that secrete IFN-gamma upon stimulation with the Ag. An important criterion is that T cell clones must recognize not only stimulator cells loaded with the protein, but also stimulator cells transduced with the MAGE-3 gene, so as to exclude the T cells that recognize contaminants generated by the protein production system. Using this approach it is possible to measure T cell frequencies as low as 10(-6). We analyzed the frequencies of anti-vaccine CD4 T cells in five metastatic melanoma patients who had been injected with a MAGE-3 protein without adjuvant and showed evidence of tumor regression. Anti-MAGE-3 CD4 T cells were detected in one of the five patients. The frequency of the anti-MAGE-3 CD4 T cells was estimated at 1/60,000 of the CD4 T cells in postvaccination blood samples, representing at least an 80-fold increase in the frequency found before immunization. The frequencies of one anti-MAGE-3 CD4 T cell clonotype were confirmed by PCR analysis on blood lymphocytes. The 13 anti-MAGE-3 clones, which corresponded to five different TCR clonotypes, recognized the same peptide presented by HLA-DR1.
Assuntos
Antígenos de Neoplasias/imunologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/patologia , Vacinas Anticâncer/imunologia , Melanoma/imunologia , Melanoma/patologia , Monitorização Imunológica/métodos , Proteínas de Neoplasias/imunologia , Sequência de Aminoácidos , Apresentação de Antígeno , Antígenos de Neoplasias/metabolismo , Antígenos de Neoplasias/uso terapêutico , Linfócitos T CD4-Positivos/metabolismo , Vacinas Anticâncer/metabolismo , Vacinas Anticâncer/uso terapêutico , Linhagem Celular Transformada , Separação Celular , Células Clonais , Técnicas de Cocultura , Inibidores do Crescimento/imunologia , Inibidores do Crescimento/metabolismo , Inibidores do Crescimento/uso terapêutico , Humanos , Interferon gama/metabolismo , Ativação Linfocitária/imunologia , Contagem de Linfócitos , Melanoma/prevenção & controle , Melanoma/secundário , Dados de Sequência Molecular , Proteínas de Neoplasias/metabolismo , Proteínas de Neoplasias/uso terapêutico , Células Tumorais CultivadasRESUMO
The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a recombinant MAGE-3 protein by subcutaneous and intradermal routes in the absence of immunologic adjuvant. Thirty-two patients with detectable metastatic melanoma expressing gene MAGE-3 were included and 30 received at least one injection with a fixed dose of a ProtD-MAGE-3 fusion protein. The immunization schedule included 6 intradermal and subcutaneous injections at 3-week intervals. Afterward, patients without major tumor progression who required other treatments received additional vaccinations at increasing time intervals. The vaccine was generally well tolerated. Among the 26 patients who received at least 4 vaccinations, we observed 1 partial response and 4 mixed responses. For these 5 responding patients, time to progression varied from 3.5 to 51+ months. An anti-MAGE-3 CD4 T-lymphocyte response was detected in 1 out of the 5 responding patients. The majority of patients had no anti-MAGE-3 antibody response. The clinical and immunologic responses generated by the vaccine are rather limited. Nevertheless, given the potential antitumor efficacy and the very mild toxicity of vaccinations, further studies combining MAGE proteins and/or peptides with potent immunologic adjuvants are warranted, not only in metastatic melanoma, but also in the adjuvant setting.
Assuntos
Antígenos de Neoplasias/administração & dosagem , Melanoma/tratamento farmacológico , Proteínas de Neoplasias/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos de Neoplasias/efeitos adversos , Antígenos de Neoplasias/uso terapêutico , Linfócitos T CD4-Positivos/imunologia , Progressão da Doença , Feminino , Humanos , Injeções Subcutâneas , Masculino , Melanoma/imunologia , Melanoma/patologia , Pessoa de Meia-Idade , Metástase Neoplásica , Proteínas de Neoplasias/efeitos adversos , Proteínas de Neoplasias/uso terapêutico , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Análise de SobrevidaRESUMO
"Cancer-germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific Ags, which have been used in therapeutic vaccination trials of cancer patients. MAGE-3 is expressed in 74% of metastatic melanoma and in 50% of carcinomas of esophagus, head and neck, bladder, and lung. We report here the identification of a new MAGE-3 peptide, which is recognized by three different CD4(+) T cell clones isolated from a melanoma patient vaccinated with a MAGE-3 protein. These clones, which express different TCRs, recognize an HLA-DR1 peptide ACYEFLWGPRALVETS, which corresponds to the MAGE-3(267-282) and the MAGE-12(267-282) protein sequences. One of the T cell clones, which expresses LFA-1 at a high level, lysed tumor cells expressing DR1 and MAGE-3. Another of these DR1-restricted CD4(+) clones recognized not only the MAGE-3/12 peptide but also homologous peptides encoded by genes MAGE-1, 2, 4, 6, 10, and 11.
Assuntos
Apresentação de Antígeno , Antígenos de Neoplasias/metabolismo , Linfócitos T CD4-Positivos/metabolismo , Vacinas Anticâncer/administração & dosagem , Vacinas Anticâncer/imunologia , Antígeno HLA-DR1/metabolismo , Melanoma/imunologia , Proteínas de Neoplasias/metabolismo , Fragmentos de Peptídeos/metabolismo , Sequência de Aminoácidos , Apresentação de Antígeno/genética , Antígenos de Neoplasias/administração & dosagem , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/imunologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/patologia , Vacinas Anticâncer/genética , Linhagem Celular Transformada , Separação Celular , Células Cultivadas , Células Clonais , Humanos , Injeções Intradérmicas , Melanoma/metabolismo , Melanoma/patologia , Melanoma/prevenção & controle , Antígenos Específicos de Melanoma , Dados de Sequência Molecular , Proteínas de Neoplasias/administração & dosagem , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/imunologia , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/imunologia , Proteínas/metabolismo , Células Tumorais Cultivadas , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/imunologiaRESUMO
In a phase I/II study, patients with solid metastatic MAGE-3-positive tumors, mainly melanoma, were vaccinated with recombinant MAGE-3 protein combined with the immunologic adjuvant AS02B comprised of MPL and QS21 in an oil-in-water emulsion. The recombinant MAGE-3 protein was made up of a partial sequence of the protein D (ProtD) antigen of Haemophilus influenzae fused to the MAGE-3 sequence. The vaccine was given intramuscularly at 3-week intervals. Patients whose tumors stabilized or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. MAGE-3 and ProtD antibody and cellular immune responses were monitored after vaccination. Ninety-six percent (23/24) of the patients vaccinated with MAGE-3 protein in AS02B adjuvant elicited a significant anti-MAGE-3 IgG antibody response after 4 vaccinations, and all developed anti-ProtD IgG antibodies. For the detection of T-cell activity, total peripheral blood mononuclear cells were restimulated in vitro with MAGE-3- or ProtD-loaded autologous mature dendritic cells. In 30% of the evaluable patients vaccinated with the adjuvanted recombinant protein, IFNgamma production was increased in response to MAGE-3, and 2 patients (14% of evaluable patients) had a concomitant increase in IL-5 production. In 37% and 43% of the patients, respectively, IFNgamma or IL-5 production was increased in response to ProtD. It is concluded that vaccination of advanced cancer patients with MAGE-3 self-antigen in AS02B adjuvant is able to elicit MAGE-3-specific antibody and a T-cell response.
Assuntos
Antígenos de Neoplasias/uso terapêutico , Vacinas Anticâncer/imunologia , Imunoterapia/métodos , Proteínas de Neoplasias/uso terapêutico , Neoplasias/imunologia , Animais , Proteínas de Bactérias/química , Western Blotting , Células CHO , Proteínas de Transporte/química , Cricetinae , Citocinas/biossíntese , Citocinas/metabolismo , Células Dendríticas/metabolismo , Ensaio de Imunoadsorção Enzimática , Escherichia coli/metabolismo , Haemophilus influenzae/metabolismo , Humanos , Imunoglobulina D/química , Insetos , Interferon gama/metabolismo , Interleucina-5/metabolismo , Leucócitos Mononucleares/metabolismo , Lipoproteínas/química , Neoplasias/metabolismo , Proteínas Recombinantes de Fusão/química , Linfócitos T/metabolismo , Fatores de Tempo , Resultado do TratamentoRESUMO
'Cancer-germline' genes such as the MAGE gene family are expressed in many tumors and in male germline cells but not in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of metastatic melanoma patients. To establish whether there is a correlation between tumoral regressions and T-cell responses against the vaccine antigen, we evaluated the responses of patients vaccinated with a MAGE-3 antigenic peptide or a recombinant virus coding for the peptide. Blood lymphocytes were stimulated with antigenic peptide followed by detection with tetramer, T-cell cloning, and TCR analysis. In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide.
Assuntos
Antígenos de Neoplasias/imunologia , Vacinas Anticâncer/uso terapêutico , Imunoterapia Ativa , Melanoma/terapia , Proteínas de Neoplasias/imunologia , Linfócitos T Citotóxicos/imunologia , Citotoxicidade Imunológica , Progressão da Doença , Evolução Fatal , Feminino , Rearranjo Gênico do Linfócito T , Vetores Genéticos/imunologia , Humanos , Imunidade Celular , Ativação Linfocitária , Melanoma/imunologia , Melanoma/patologia , Metástase Neoplásica , Fragmentos de Peptídeos/imunologia , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Indução de Remissão , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/terapia , Resultado do Tratamento , Vacinação , Vacinas de Subunidades Antigênicas/imunologia , Vacinas Sintéticas/imunologia , Vacinas ViraisRESUMO
Aborda a contribuição científica de Pasteur, desde seus estudos em cristalografia que marcaram o começo de sua carreira científica, para se deter a seguir na história do Instituto Pasteur, ressaltando o papel da instituição na pesquisa e nas ações de saúde, a contribuição dos principais colaboradores de Pasteur, a importância do mecenato e a presença de brasileiros na instituição.